40 articles - From Friday Aug 12 2022 to Friday Aug 19 2022
Guidelines, position statements, white papers, technical reviews, consensus statements, etc…
| Ann Rheum Dis |
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. The document provides a comprehensive consensus on the use of IL-6 inhibition to treat inflammatory disorders to inform healthcare professionals (including researchers), patients, administrators and payers. |
| Rheumatology (Oxford) |
Comparing Canadian pediatric rheumatology practice to the 2019 ACR Juvenile Idiopathic Arthritis guidelines. Results from the CAPRI Registry. Canadian pediatric rheumatology practices were in line with many 2019 JIA Guidelines recommendations before their publication, except for frequent use of oral methotrexate and infrequent direct escalation from NSAIDs to biologic DMARDs in sacroiliitis and enthesitis. |
meta-analyses and systematic reviews
| Rheumatology (Oxford) |
Clinical and therapeutic diversity in adult chronic nonbacterial osteomyelitis (CNO) of the sternocostoclavicular region: a meta-analysis. CNO/SCCH literature proves heterogeneous regarding diagnostics and treatment. Timely diagnosis is challenging and mainly follows from increased isotope uptake on nuclear examination. Biopsies, autoantibodies and HLA-status are non-contributory, and biochemical inflammation only variably detected. Based on reported data, bisphosphonates and biologicals seem reasonably effective, but due to limitations in design and heterogeneity between studies the precise magnitude of their effect is uncertain. Fundamentally, international consensus seems imperative to advance clinical care for CNO/SCCH. |
Sexual dysfunction in women with systemic autoimmune rheumatic disorders: a systematic review and meta-analysis. Sexual function in females with SARDs seems to be severely impaired, irrespective of the type of SARD. Screening and treatment of SD in females with SARDs should become an integral part of healthcare clinical practice. |
RCT, clinical trials, retrospective studies, etc…
| Ann Rheum Dis |
Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission. Patients with AAV treated with rituximab achieved remission less frequently when concentrations of sLag-3 were low and concentrations of sCD27 were high. Higher concentrations of sTim-3, sCD27 and sBTLA at baseline predicted relapse in patients treated with rituximab. These results require confirmation but may contribute to a personalised treatment approach of AAV. |
Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON. The safety profile of nintedanib over 52 weeks of SENSCIS-ON was consistent with that reported in SENSCIS. The change in FVC over 52 weeks of SENSCIS-ON was similar to that observed in the nintedanib group of SENSCIS. |
Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study. A fourth vaccine dose is immunogenic in a fraction of rituximab-treated patients. Continuation of rituximab treatment reduced humoral immune response, suggesting that rituximab affects a second booster vaccination. It might therefore be considered to postpone rituximab treatment in clinically stable patients. |
Implementation of recommendations in rheumatic and musculoskeletal diseases: considerations for development and uptake. This article describes the principles of implementation science to facilitate and optimise the implementation of clinical recommendations in RMDs. Embedding implementation science methods and techniques into recommendation development and daily practice can help maximise the likelihood that implementation is successful in improving the quality of healthcare and healthcare services. |
Isolated axial disease in psoriatic arthritis and ankylosing spondylitis with psoriasis. Isolated axial PsA and AS with psoriasis are uncommon. HLA-B*27 positivity is associated with isolated axial PsA and may identify those who develop peripheral disease over time. Isolated axial PsA is associated with better functional status. Isolated axial PsA appears clinically distinct from isolated axial AS with psoriasis. |
Loss-of-function variants in SAT1 cause X-linked childhood-onset systemic lupus erythematosus. Effects of a splice site variant and a frameshift variant were assessed using a Minigene assay and CRISPR/Cas9-mediated knock-in (KI) mice, respectively. Results The two familial ultra-rare, predicted loss-of-function (LOF) LOF variants as new monogenic causes for SLE. |
Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. The post hoc hierarchical analysis of the primary and key secondary end points in a per-protocol population, complemented by the exploratory analyses of multiple other secondary end points, support that low-dose IL-2 is beneficial in active SLE. |
Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-a. The production of non-neutralising and neutralising anti-IFN-I antibodies in SLE is likely to be a consequence of SLE-associated high IFN-I serum levels, with a beneficial effect on disease activity, yet a greater viral risk. This finding reinforces the recommendations for vaccination against SARS-CoV-2 in SLE. |
Pregnancy and neonatal outcomes in women with axial spondyloarthritis: pooled data analysis from the European Network of Pregnancy Registries in Rheumatology (EuNeP). Pooled rates of most outcomes were better than what had been reported in the literature and within expected rates of those reported for the general population. Pre-conception counselling, planned pregnancies and a tight management in expert centres applying a tailored treatment approach may have contributed to the favourable pregnancy outcomes. |
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Secukinumab demonstrated significantly longer time to disease flare than placebo in children with ERA and JPsA with a consistent safety profile with the adult indications of psoriatic arthritis and axial spondyloarthritis. |
| Arthritis Res Ther |
Abatacept downregulates Fc The therapeutic effects of abatacept on RA are mediated, in part, by the downregulation of CD64/Fc |
Serum granulocyte-macrophage colony-stimulating factor (GM-CSF) is increased in patients with active radiographic axial spondyloarthritis and persists despite anti-TNF treatment. GM-CSF is increased in patients with active AS and strongly correlates with disease activity. TNF inhibition does not affect GM-SCF levels, despite improving disease activity. GM-CSF may represent an important pathway responsible for residual inflammation during TNF blockade, but also a potential target of JAK inhibitors, explaining their efficacy in r-axSpA. |
| Arthritis Rheumatol |
Decrease in body mass index is associated with reduced incidence and progression of the structural defects of knee osteoarthritis: a prospective multi-cohort study. BMI decrease is independently associated with lower odds of onset and progression of the structural defects of knee osteoarthritis, and could be a component in preventing the onset or worsening of knee osteoarthritis. |
| Rheumatology (Oxford) |
Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features. Anti-FHL1 autoantibodies are present in ~11% of juvenile IIM patients and commonly co-occur with MAAs, including anti-Ro52 autoantibodies. In contrast to adult IIM, anti-FHL1 autoantibodies in juvenile myositis are associated with V-sign rash but not with other distinctive clinical features or worse outcomes. |
Antiphospholipid Antibodies in Patients with Calcific Aortic Valve Stenosis. aPL IgG was more common in CAVS patients compared with matched controls and aPL positivity was associated with altered AV transcriptomics related to local disease progression and interferon pathways. Further studies should aim to establish aPL as a possible risk marker and/or causal factor for CAVS and could offer new precision therapeutic targets. |
AOSD Endotypes based on immune cell profiles: patient stratification with hierarchical clustering analysis. Hierarchical cluster analysis of peripheral immune cells classified AOSD into three disease-related endotypes. Group 3 showed higher systemic score and poorer treatment responses. |
Association between popliteal artery wall thickness and structural progression in patients with symptomatic knee osteoarthritis. The findings support a role for vascular pathology in the progression of knee osteoarthritis. Targeting atherosclerosis has the potential to improve outcomes in knee osteoarthritis. |
Comparing MRI and conventional radiography for the detection of structural changes indicative of axial spondyloarthritis in the ASAS cohort. Structural lesions of SIJ detected by MRI demonstrated better diagnostic performance and better inter-reader reliability compared with conventional radiography. |
Does expert opinion match the definition of Lupus Low Disease Activity State? prospective analysis of 500 patients from a Spanish multicentre cohort. Almost two thirds of SLE patients were in LLDAS. There was a fair correlation between LLDAS and the physician's evaluation. This agreement improves for patients fulfilling the LLDAS criteria. The discordance between both at defining lupus low activity, the demonstrated association of LLDAS with better outcomes and the fact that LLDAS is more stringent than physician's opinion imply that we should use the LLDAS as a treat to target goal. |
Mobilization with reduced cyclophosphamide for autologous stem cell transplantation is feasible in patients with systemic sclerosis. Our data demonstrate that a reduced cyclophosphamide mobilization regimen seems to be feasible. Risk factors for poor mobilization might be low bodyweight, prior rituximab therapy and cardiac involvement. |
Patient-individual tapering of DMARDs in rheumatoid arthritis patients in a real-world setting. Individual tapering of DMARDs does not increase the average risk of experiencing flares or loss of remission. Encouraging rheumatologists and patients to apply tapering in shared decision may be a feasible approach to allow individualisation of treatment in RA. |
Rituximab as maintenance therapy following remission induction in relapsing or refractory systemic lupus erythematosus. This multicentre prospective cohort study demonstrated that long-term RTX maintenance therapy has high efficacy and acceptable safety in relapsing or refractory SLE patients who had a clinical response to RTX induction therapy. |
The effect of group-based cognitive behavioural therapy for insomnia in patients with rheumatoid arthritis: A randomised controlled trial. Nurse-led group-based CBT-I did not lead to an effect on sleep efficiency objectively measured with PSG. However, CBT-I showed improvement on al patient-reported key secondary sleep- and RA-related outcomes measured at week 26.ClinicalTrials.gov, NCT03766100. |
Time-dependent changes in RPILD and mortality risk in anti-MDA5+ DM patients: a cohort study of 272 cases in China. These results suggest significant, time-dependent changes in RPILD and mortality risk in anti-MDA5+ DM patients, providing a cutoff time window to estimate disease progression and poor prognosis. |
Urinary CD163 is a marker of active kidney disease in childhood-onset lupus nephritis. Thus, urine CD163 emerges as a promising marker for identifying cSLE patients with active kidney disease. Longitudinal studies are warranted to validate the clinical utility of urine CD163 in tracking kidney disease activity in children with lupus. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Arthritis Res Ther |
Role of NLRP3 inflammasome in systemic sclerosis. Here, we review the studies focused on NLRP3 inflammasome activation, its association with innate and adaptive immune cells, endothelium injury, and differentiation of fibroblasts in SSc. Furthermore, we summarize the prospect of therapy targeting NLRP3 pathway. |
Letters to the editors and authors’ replies
| Arthritis Care Res (Hoboken) |
| Arthritis Rheumatol |
all remaining publications eg case reports, images of the month, etc…
| Ann Rheum Dis |
| Rheumatology (Oxford) |